LEADER 02707nam 2200409z- 450 001 9910261137903321 005 20231214133132.0 035 $a(CKB)4100000002484713 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/54175 035 $a(EXLCZ)994100000002484713 100 $a20202102d2017 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aMycoplasma pneumoniae Clinical Manifestations, Microbiology, and Immunology 210 $cFrontiers Media SA$d2017 215 $a1 electronic resource (175 p.) 225 1 $aFrontiers Research Topics 311 $a2-88945-362-6 330 $aMycoplasma pneumoniae (Mp) is a major human pathogen that causes both upper and lower respiratory infections, and is one of the leading causes of community acquired pneumonia (CAP), accounting for 11?15% of CAP throughout the world. Additionally it is known to induce an inflammatory process which depends on several mechanisms such as virulence of Mp (lipoproteins, community acquired respiratory distress syndrome (CARDS) toxin, oxidative products) and host defenses (cellular immunity and humoral immunity). Although it is a common pathogen, the pathogenesis for Mp infections is not yet fully understood. From the clinical point of view, since the pioneer studies in the 1960s and 1970s on the clinical presentation of Mp associated disease, the diagnostics approaches have changed dramatically leading to a better understanding of the clinical presentation and new issues have emerged - such as antibiotics resistance. The purpose of this Frontiers ebook is to thoroughly review and discuss the clinical presentation in view of the improved diagnostics, microbiological and immunological analysis of Mp infections, with focus on the history of Mp, clinical features of disease, bacterial structure of Mp and mechanism of gliding, clinical and laboratory diagnostics, the role of lipoproteins and Toll-like receptor, CARDS toxin, subtyping of Mp isolates and genome analysis, macrolide resistance and treatment. 610 $apathogenesis 610 $aepidemiology 610 $atreatment 610 $aclinical presentation antimicrobial resistance 610 $aMycoplasma pneumoniae 610 $aoutcome 700 $aTakashi Shimizu$4auth$01311261 702 $aRan Nir-Paz$4auth 702 $aTakeshi Saraya$4auth 702 $aAnnemarie Van Rossum$4auth 702 $aCecile Bebear$4auth 906 $aBOOK 912 $a9910261137903321 996 $aMycoplasma pneumoniae Clinical Manifestations, Microbiology, and Immunology$93030068 997 $aUNINA